PDCD1 and neoplasm: As shown in Figure 5A, the PD-1 deficient GPC3-CAR T cells showed significantly (P < 0.01) stronger tumor-lysis activity against GPC3-positive PLC/PRF/5 and SK-HEP-1/GPC3 HCC cells compared with wild-type GPC3-CAR T cells, and the anti-tumor activities of PD-1 deficient GPC3-CAR T cells against PLC/PRF/5 and SK-HEP-1/GPC3 HCC cells were 1.25 and 1.30 times higher than those of wild-type GPC3-CAR T cells, respectively, indicating that the disruption of PD-1 enhanced the cytotoxic activity of GPC3-CAR T cells.